预防与治疗胃癌腹膜转移的若干关键问题

摘要/Abstract

中图分类号:

R735.2

朱正纲. 预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(01): 1-6.

ZHU Zhenggang. Key issues in prevention and treatment of peritoneal metastatic gastric cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 1-6.

参考文献38

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3):145-149.
[3]	朱正纲. 胃癌腹膜转移综合治疗的若干进展[J]. 中华实验外科杂志, 2015, 32(9):2039-2041.
[4]	朱正纲. 胃癌腹膜转移转化性治疗的临床意义和实践要点[J]. 中华胃肠外科杂志, 2017, 20(10):1094-1098.
[5]	Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry[J]. Gastric Cancer, 2013, 16(1):1-27. doi:10.1007/s10120-012-0163-4pmid:22729699
[6]	de Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review[J]. J Surg Oncol, 2014, 110(3):291-297. doi:10.1002/jso.23632pmid:24850538
[7]	Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma[J]. Br J Surg, 2000, 87(2):236-242.
[8]	Tanaka T, Kumagai K, Shimizu K, et al. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis[J]. J Surg Oncol, 2000, 75(3):165-171. pmid:11088047
[9]	Huang B, Sun Z, Wang ZN, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database[J]. BMC Cancer, 2013, 13:57.
[10]	Lee JH, Son SY, Lee CM, et al. Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy[J]. Gastric Cancer, 2014, 17(3):529-536.
[11]	中国抗癌协会胃癌专业委员会. 胃癌腹膜转移防治中国专家共识[J]. 中华胃肠外科杂志, 2017, 20(5):481-490.
[12]	Lavonius MI, Gullichsen R, Salo S, et al. Staging of gastric cancer: a study with spiral computed tomography, ultrasonography, laparoscopy, and laparoscopic ultrasonography[J]. Surg Laparosc Endosc Percutan Tech, 2002, 12(2):77-81.
[13]	NCCN Clinical Practice Guidelines in Oncology-Gastric Cancer(Version 1.2019)[EB/OL]. [2020-12-03]. https://www.nccn.org.
[14]	Hu YE, Deng ZW, Liu H, et al. Staging laparoscopy improves treatment decision-making for advanced gastric cancer[J]. World J Gastroenterol, 2016, 22(5):1859-1868.
[15]	Bottcher KA, Kraemer SJM, Feussner H, et al. Laparoscopic diagnosis of peritoneal carcinoma in gastric cancer[M]//Yutaka Yonemura. Peritoneal dissemination-Mole-cular mechanisms and the latest therapy. Kanazawa, Japan: Maeda Shoten, 1998:147-152.
[16]	李进, 秦叔逵, 马军, 等. 胃癌诊疗指南2019-中国临床肿瘤学会(CSCO)常见恶性肿瘤诊疗指南2019[M]. 北京: 人民卫生出版社, 2019:199-240.
[17]	Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology(CSCO): clinical guidelines for the diag-nosis and treatment of gastric cancer[J]. Cancer Commun(Lond), 2019, 39(1):10-40.
[18]	Beeharry MK, Ni ZT, Yang ZY, et al. Study protocol of a multicenter phase Ⅲ randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastriccancer (AGC): dragon Ⅱ trial[J]. BMC Cancer, 2020, 20:224-232.
[19]	朱正纲, 汤睿, 燕敏, 等. 术中腹腔内温热化疗对进展期胃癌的临床疗效研究[J]. 中华胃肠外科杂志, 2006, 9(1):26-30.
[20]	Zhu ZG, Tang R, Yan M, et al. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study[J]. Dig Surg, 2006, 23(1-2):93-102.
[21]	Beeharry MK, Zhu ZL, Liu WT, et al. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study[J]. BMC Cancer, 2019, 19(1):932-941
[22]	Beeharry MK, Zhu ZL, Liu WT, et al. Correction to: prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study[J]. BMC Cancer, 2019, 19(1):1256.
[23]	詹宏杰, 梁寒, 王宝贵, 等. 60例进展期胃癌术中腹腔热灌注化疗的临床观察[J]. 中国肿瘤临床, 2010, 37(4):229-231.
[24]	倪震天, 李琛, 严超, 等. 手术联合术中腹腔温热化疗治疗进展期胃癌疗效及安全性 Meta分析[J]. 中华胃肠外科杂志, 2016, 19(12):1406-1413.
[25]	Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients[J]. Cancer Res Treat, 2014, 46(3):270-279.
[26]	朱正纲. 进展期胃癌围手术期治疗全程管理的若干要点[J]. 中华胃肠外科杂志, 2020, 23(2):115-122.
[27]	Sugarbaker PH, 杨智冉, 李雁. 国际腹膜癌治疗指南:肿瘤细胞减灭术加腹腔化疗临床路径[J]. 中国肿瘤临床, 2020, 47(11):541-551.
[28]	Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy[J]. Ann Surg Oncol, 2010, 17(9):2370-2377.
[29]	Rihuete Caro C, Manzanedo I, Pereira F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis[J]. Eur J Surg Oncol, 2018, 44(11):1805-1810.
[30]	Brandl A, Yonemura Y, Glehen O, et al. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI[J]. Eur J Surg Oncol, 2021, 47(1):172-180.
[31]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
[32]	Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-a meta-analysis of randomized and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer[J]. Eur J Cancer, 2017, 79:1-14 doi:S0959-8049(17)30868-7pmid:28456089
[33]	Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer[J]. Ann Surg Oncol, 2017, 24(2):478-485. doi:10.1245/s10434-016-5487-6pmid:27506661
[34]	Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis[J]. Cancer, 2013, 119(18):3354-3358. doi:10.1002/cncr.28204pmid:23798046
[35]	Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
[36]	Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressu-rized aerosol as an alternative to liquid solution: first evidence for efficacy[J]. Ann Surg Oncol, 2014, 21(2):553-559.
[37]	Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rational, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[38]	Chia DKA, So JBY. Recent advances in intra-peritoneal chemotherapy for gastric cancer[J]. J Gastric Cancer, 2020, 20(2):115-126.

预防与治疗胃癌腹膜转移的若干关键问题

Key issues in prevention and treatment of peritoneal metastatic gastric cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献38

相关文章15

编辑推荐

Metrics

本文评价

[1]	严超, 陆晟, 燕敏, 朱正纲.《日本胃癌治疗指南2021（第6版）》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354.
[2]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟.预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[3]	孙强, 姚骏, 张鑫, 杜杉珊, 王伟军.近端胃切除抗反流消化道重建方式的研究进展[J]. 外科理论与实践, 2023, 28(04): 388-393.
[4]	胡文庆, 杨垠浩, 崔鹏, 魏伟.食管胃结合部腺癌腹腔镜经腹-左膈肌路径近端胃加食管下段切除高位消化道重建现状[J]. 外科理论与实践, 2023, 28(03): 226-232.
[5]	燕速, 郑民华.中国单孔及减孔腹腔镜胃癌手术实践[J]. 外科理论与实践, 2023, 28(03): 233-239.
[6]	范清泉, 宋晓玲, 顾钧.外泌体在胃癌中的研究展望[J]. 外科理论与实践, 2023, 28(02): 177-180.
[7]	颜凌, 王凌云, 陈勇, 杜联军.双能CT图像深度学习重建算法在胃癌术前T分期中的应用[J]. 诊断学理论与实践, 2023, 22(02): 154-159.
[8]	徐凯, 李百文.早期胃癌及胃癌前病变的内镜黏膜下剥离术治疗[J]. 内科理论与实践, 2023, 18(02): 102-106.
[9]	胡端敏.内镜超声检查对胃癌浸润深度的判断及影响因素[J]. 诊断学理论与实践, 2023, 22(01): 85-88.
[10]	李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚.胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16.
[11]	卢一鸣, 熊建平, 田艳涛.晚期胃癌转化治疗的发展现状与研究前景[J]. 外科理论与实践, 2023, 28(01): 17-23.
[12]	朱正纲.胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
[13]	赵法之, 赵平.胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30.
[14]	李国立, 郭飞龙.动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.
[15]	刘文韬, 刘福坤.中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41.